Pharmaceutical

EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia

The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.

Nov 21, 2024 - 06:00
EC marketing authorisation granted to Pfizer’s HYMPAVZI for haemophilia
The EC has granted marketing authorisation for Pfizer's anti-tissue factor pathway inhibitor (anti-TFPI), HYMPAVZI to treat haemophilia.
Read the original article

Tags:

Previous Article

Kura Oncology partners Kyowa Kirin to advance AML treatment

Next Article

Leading sales enablement, prospecting and automation providers and technology so...

What's Your Reaction?

like

dislike

love

funny

angry

sad

wow

Related Posts

STAT+: Vivek Ramaswamy’s brashness made waves in the Republican debate. He did the same in biotech

STAT+: Vivek Ramaswamy’s brashness made waves in the Re...

Aug 27, 2023

AbbVie wins UK NICE endorsement for subcutaneous Tepkinly in DLBCL

AbbVie wins UK NICE endorsement for subcutaneous Tepkin...

Feb 2, 2024

STAT+: Pharmalittle: Novartis is losing its chief commercial officer; vaccine experts urge more inclusivity in clinical trials

STAT+: Pharmalittle: Novartis is losing its chief comme...

Sep 6, 2023